Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.82 |
| ▸ | MEN1 | O00255 | 3/20 | 0.82 |
| ▸ | RAB9A | P51151 | 1/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | CCR3 | P51677 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5270225 | 0.92 | KMT2A (0.70) | KMT2AMEN1RAB9AOPRM1ACHE | |
| SCHEMBL16225933 | 0.92 | KMT2A (0.83) | KMT2AMEN1RAB9AOPRM1ACHE | |
| SCHEMBL16757213 | 0.90 | KMT2A (1.00) | KMT2AMEN1RAB9AALDH1A1OPRM1 | |
| SCHEMBL16757436 | 0.88 | KMT2A (0.82) | KMT2AMEN1RAB9AALDH1A1OPRM1 | |
| SCHEMBL16757422 | 0.88 | KMT2A (0.73) | KMT2AMEN1RAB9AALDH1A1OPRM1 | |
| SCHEMBL16757278 | 0.88 | KMT2A (0.85) | KMT2AMEN1RAB9AALDH1A1OPRM1 | |
| SCHEMBL16757237 | 0.87 | KMT2A (0.75) | KMT2AMEN1RAB9AALDH1A1OPRM1 | |
| SCHEMBL16757194 | 0.85 | KMT2A (0.72) | KMT2AMEN1RAB9AALDH1A1OPRM1 | |
| SCHEMBL16757276 | 0.83 | KMT2A (0.67) | KMT2AMEN1RAB9AALDH1A1OPRM1 | |
| SCHEMBL16769445 | 0.83 | KMT2A (0.67) | KMT2AMEN1RAB9AALDH1A1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2017-01-05 | — | — | US | disclosed |
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2017-01-05 | — | — | US | disclosed |
| WO-2015080949-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-06-04 | — | — | WO | disclosed |
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | KMT2A 2536/4885MEN1 4777/4885RAB9A 2017/4885 |
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | NCOR1, RRP15, NCOA1 | KMT2A 1974/4885MEN1 3157/4885RAB9A 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.